Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 4Thoracic 1Sarcoma 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Melanoma 135Lymphoma, T-Cell, Cutaneous 45Lymphoma, Non-Hodgkin 37Lymphoma, Follicular 36Precursor Cell Lymphoblastic Leukemia-Lymphoma 35Lymphoma, Large B-Cell, Diffuse 35Lymphoma, Large-Cell, Immunoblastic 34Leukemia, Lymphocytic, Chronic, B-Cell 34Lymphoma, Mantle-Cell 33Lymphoma, B-Cell, Marginal Zone 33Burkitt Lymphoma 33Lymphoma 32Leukemia, Myeloid, Acute 32Hodgkin Disease 31Mycosis Fungoides 30Sezary Syndrome 29Multiple Myeloma 28Leukemia, Myeloid, Accelerated Phase 26Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 24Neoplasm Metastasis 24Leukemia, Myeloid, Chronic-Phase 24Leukemia 23Myelodysplastic Syndromes 22Lymphoma, Large-Cell, Anaplastic 22Congenital Abnormalities 22Blast Crisis 22Skin Neoplasms 20Immunoblastic Lymphadenopathy 20Myeloproliferative Disorders 19Recurrence 18

Interventions

fludarabine phosphate 1fludarabine 1entinostat 1carboxyamido-triazole 1aldesleukin 1Thalidomide 1Paclitaxel 1Fentanyl 1Docetaxel 1Cyclophosphamide 190Y-octreotide, DOTA-Tyr(3)- 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Meningioma × Cyclophosphamide × Dermatologic × Clear all
NCT01967823 2021-03-24

T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
11 enrolled 12 charts
BreastCNSDermatologicGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Liver Neoplasms, Melanoma, Meningioma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡